MX2008012317A - Uso de estrobilurinas para el tratamiento de trastornos del metabolismo del hierro. - Google Patents

Uso de estrobilurinas para el tratamiento de trastornos del metabolismo del hierro.

Info

Publication number
MX2008012317A
MX2008012317A MX2008012317A MX2008012317A MX2008012317A MX 2008012317 A MX2008012317 A MX 2008012317A MX 2008012317 A MX2008012317 A MX 2008012317A MX 2008012317 A MX2008012317 A MX 2008012317A MX 2008012317 A MX2008012317 A MX 2008012317A
Authority
MX
Mexico
Prior art keywords
strobilurins
iron metabolism
malfunctions
treating
treating malfunctions
Prior art date
Application number
MX2008012317A
Other languages
English (en)
Inventor
Bennard Van Ravenzwaay
Werner Mellert
Klaus Deckardt
Heinz Kieczka
Georgia Coelho Palermo Cunha
Original Assignee
Basf Se
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38284013&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2008012317(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Basf Se filed Critical Basf Se
Publication of MX2008012317A publication Critical patent/MX2008012317A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Los derivados de estrobolurina se pueden emplear para el tratamiento y/o evitar el funcionamiento defectuoso del metabolismo del hierro en los mamíferos.
MX2008012317A 2006-03-29 2007-03-27 Uso de estrobilurinas para el tratamiento de trastornos del metabolismo del hierro. MX2008012317A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06111933 2006-03-29
PCT/EP2007/052917 WO2007113170A1 (de) 2006-03-29 2007-03-27 Verwendung von strobilurinen zur behandlung von störungen des eisen-stoffwechsels

Publications (1)

Publication Number Publication Date
MX2008012317A true MX2008012317A (es) 2008-10-10

Family

ID=38284013

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008012317A MX2008012317A (es) 2006-03-29 2007-03-27 Uso de estrobilurinas para el tratamiento de trastornos del metabolismo del hierro.

Country Status (16)

Country Link
US (1) US20100234366A1 (es)
EP (1) EP2001555A1 (es)
JP (1) JP2009531379A (es)
KR (1) KR20080111021A (es)
CN (1) CN101448550A (es)
AR (1) AR060178A1 (es)
AU (1) AU2007233829A1 (es)
BR (1) BRPI0710209A2 (es)
CA (1) CA2646209C (es)
CL (1) CL2007000836A1 (es)
EA (1) EA200801940A1 (es)
IL (1) IL194159A0 (es)
MX (1) MX2008012317A (es)
TW (1) TW200812592A (es)
WO (1) WO2007113170A1 (es)
ZA (1) ZA200809192B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101290745B1 (ko) 2010-06-03 2013-07-29 한국해양과학기술원 라말린을 함유하는 염증질환 또는 면역질환의 예방 또는 치료용 약학 조성물
US11433070B2 (en) 2019-06-28 2022-09-06 The Procter & Gamble Company Synergistic anti-inflammatory compositions
US11980612B2 (en) 2020-06-26 2024-05-14 The Procter & Gamble Company Synergistic anti-inflammatory compositions
US11701316B2 (en) 2020-12-18 2023-07-18 The Procter & Gamble Company Synergistic anti-inflammatory compositions

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US37873A (en) * 1863-03-10 Improvement in hay-presses
US33989A (en) * 1861-12-24 Improvement it machines for punching boiler-plates
US37839A (en) * 1863-03-03 Improved spoke-machine
DE3623921A1 (de) * 1986-07-16 1988-01-21 Basf Ag Oximether und diese enthaltende fungizide
DE3705389A1 (de) * 1987-02-20 1988-09-01 Basf Ag Substituierte crotonsaeureester und diese enthaltende fungizide
DE3823991A1 (de) * 1988-07-15 1990-02-15 Basf Ag Heterocyclisch substituierte (alpha)-aryl-acrylsaeureester und fungizide, die diese verbindungen enthalten
US5194438A (en) * 1988-07-15 1993-03-16 Basf Aktiengesellschaft α-arylacrylates substituted by a trifluoromethylpyrimidinyloxy radical, fungicidal compositions and methods
DE3905911A1 (de) * 1989-02-25 1990-08-30 Basf Ag Neue ss-methoxyacrylate, ihre herstellung und verwendung
PH11991042549B1 (es) * 1990-06-05 2000-12-04
DE59109047D1 (de) * 1990-06-27 1998-10-08 Basf Ag O-Benzyl-Oximether und diese Verbindungen enthaltende Pflanzenschutzmittel
DE4030038A1 (de) * 1990-09-22 1992-03-26 Basf Ag Ortho-substituierte phenylessigsaeureamide
DE4117371A1 (de) * 1991-05-28 1992-12-03 Basf Ag Antimykotische mittel, die phenylessigsaeurederivate enthalten
DK0624155T4 (da) * 1992-01-29 2003-01-06 Basf Ag Carbamater og plantebeskyttelsesmidler indeholdende disse
DE4318917A1 (de) * 1993-06-07 1994-12-08 Bayer Ag 2-Oximino-2-phenyl-acetamide
AU681932B2 (en) * 1994-02-04 1997-09-11 Basf Aktiengesellschaft Phenyl acetic acid derivatives, process and intermediate products for their production and agents containing them
EP0945431A3 (de) * 1994-02-04 2004-08-18 Basf Aktiengesellschaft Verfahren und Zwischenprodukte zur Herstellung von Phenylessigsäurederivaten
DE4423612A1 (de) * 1994-07-06 1996-01-11 Basf Ag 2-[(Dihydro)pyrazolyl-3'-oxymethylen]-anilide, Verfahren zu ihrer Herstelung und ihre Verwendung
DE19539324A1 (de) * 1995-10-23 1997-04-24 Basf Ag Phenylessigsäurederivate, Verfahren und Zwischenprodukte zu ihrer Herstellung und sie enthaltende Mittel
US6084120A (en) * 1997-07-09 2000-07-04 Hoffmann-La Roche Inc. β-Alkoxyacrylates against malaria
IT1303688B1 (it) * 1998-11-02 2001-02-23 Medidom Lab Derivati aromatici e relativi complessi di fe(iii) atti all'usocome agenti normalizzanti del livello di ferro nell'organismo.
US6646157B2 (en) * 1999-12-21 2003-11-11 Geltex Pharmaceuticals, Inc. Method for making HBED
BR0308325A8 (pt) * 2002-03-11 2018-03-20 Basf Se método para imunizar plantas contra bacterioses, e, uso de um composto
DE10211428A1 (de) * 2002-03-15 2003-10-23 Bayer Ag Bekämpfung von Parasiten an Tieren durch Halogenpyrimidine
WO2004004702A2 (en) * 2002-07-09 2004-01-15 The Scripps Research Institute Method to inhibit ischemia and reperfusion injury
US20050032903A1 (en) * 2003-08-08 2005-02-10 Suarez-Cervieri Miguel Octavio Method for controlling fungal sieases in legumes
KR100624238B1 (ko) * 2004-06-22 2006-09-19 한국화학연구원 알파-아릴메톡시아크릴레이트 유도체를 함유하는 대사성골 질환의 예방 및 치료용 약학 조성물

Also Published As

Publication number Publication date
CN101448550A (zh) 2009-06-03
ZA200809192B (en) 2010-01-27
EA200801940A1 (ru) 2009-04-28
AR060178A1 (es) 2008-05-28
CA2646209C (en) 2011-08-16
EP2001555A1 (de) 2008-12-17
TW200812592A (en) 2008-03-16
CL2007000836A1 (es) 2008-05-23
KR20080111021A (ko) 2008-12-22
CA2646209A1 (en) 2007-10-11
AU2007233829A1 (en) 2007-10-11
BRPI0710209A2 (pt) 2011-05-24
WO2007113170A1 (de) 2007-10-11
IL194159A0 (en) 2011-08-01
US20100234366A1 (en) 2010-09-16
JP2009531379A (ja) 2009-09-03

Similar Documents

Publication Publication Date Title
ZA200803048B (en) Microangiopathy treatment and prevention
EP1883416A4 (en) COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING CONDITIONS RELATED TO INFLAMMATION
EP2214495A4 (en) NATURALLY PHOTODYNAMIC ACTIVE SUBSTANCES AND ITS USE
ZA200702421B (en) Iron complex for use in the treatment and/or prevention of nutritional disorders
ZA201002246B (en) Benzoquinone derivative e3330 in combination with chemotherapeutic agents for the treatment of cancer and angiogenesis
IL201211A (en) K3 ip-alpha quinoxaline inhibitors for use in combination with chemotherapeutic agents for use in the treatment of cancer
EP2087094A4 (en) LACTOBACILLUS FERMENTUM ESS-1, DSM17851 AND ITS USE IN THE TREATMENT AND / OR PREVENTION OF CANDIDOSIS AND URINARY TRACT INFECTIONS
WO2009064444A9 (en) Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents
MX2012003837A (es) Cartucho de tratamiento de agua.
EP2493497A4 (en) INHIBITION OF NOTCH FOR THE TREATMENT AND PREVENTION OF OBESITY AND METABOLIC SYNDROME
PL1921077T3 (pl) Środek do zapobiegania i/lub leczenia zaburzenia snu
PL2564872T3 (pl) Mazindol sam lub w kombinacji z żelazem do leczenia deficytu uwagi/nadpobudliwości
ZA200900210B (en) Compositions and methods for preventing or treating cardiovascular diseases in felines with hyperthyroidism
EP2091540A4 (en) PYRAZOLYL DERIVATIVES WITH ANALGETIC EFFECT FOR THE TREATMENT OR PROPHYLAXIS OF PAIN
EP2030615A3 (en) Ribonucleotide reductase inhibitors for use in the treatment or prevention of neuroinflammatory or autoimmune diseases
EP2164490A4 (en) PYRAZOLYL DERIVATIVES WITH ANALGESIC PROPERTIES AND THEREFORE USEFUL IN THE TREATMENT OR PROPHYLAXIS OF PAIN
JO3262B1 (ar) توليفة من ديسيتابين مع مثبط سيتيدين دي أميناز واستخدامها في علاج السرطان
PL3216457T3 (pl) Związki i sposoby zapobiegania lub leczenia restenozy
EP2002012A4 (en) METHOD FOR THE TREATMENT, REDUCTION AND INHIBITION OF AGE SKIN IN THE SKIN
WO2012073047A3 (en) Compositions and methods
MX2008012317A (es) Uso de estrobilurinas para el tratamiento de trastornos del metabolismo del hierro.
EP2301558A4 (en) MEANS FOR THE PREVENTION AND / OR TREATMENT OF ATOPIC DERMATITIS
IL188404A0 (en) Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
GB2460976B (en) Methods of determining compounds useful in the treatment of bipolar disorder and methods of treating such disorders
MX2009004142A (es) Metodo para prevenir o tratar sindrome metabolico.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal